Dr. Disimone is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8415 N Pima Rd
Ste 165
Scottsdale, AZ 85258Phone+1 480-223-9805Fax+1 480-270-6020
Education & Training
- University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 1999 - 2002
- University of California, Davis, School of MedicineClass of 1999
Certifications & Licensure
- CA State Medical License 2018 - 2026
- AZ State Medical License 2005 - 2025
Awards, Honors, & Recognition
- Top Doctors:Arizona State Castle Connolly, 2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
Publications & Presentations
PubMed
- 98 citationsLenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.Chung-Han Lee, Amishi Yogesh Shah, Drew W. Rasco, Arpit Rao, Matthew H. Taylor
The Lancet. Oncology. 2021-07-01 - 65 citationsOpen-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, James M G Larkin, Rustem A Gafanov
Journal of Clinical Oncology. 2021-03-20 - 312 citationsLenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial CancerVicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier
Journal of Clinical Oncology. 2020-03-13
Press Mentions
- The 100 Best Doctors in Arizona for 2024December 15th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: